Trial
NCT00594230
LBH589 in Refractory Myelodysplastic Syndromes (MDS)
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
SCRI Development Innovations, LLC
Collaborators
Novartis Pharmaceuticals
Condition
Myelodysplastic Syndromes (MDS)
Intervention
Panobinostat
Why stopped
Per protocol, the results of a planned interim analysis demonstrated insufficient efficacy and led to early termination of the study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-11-22